3-(alpha-D-galactopyranosyloxy)-N-(3-{4-[3-({2-[(3-{4-[3-({[3-(hexopyranosyloxy)-5-nitrophenyl]carbonyl}amino)propyl]piperazin-1-yl}propyl)amino]-3,4-dioxocyclobut-1-en-1-yl}amino)propyl]piperazin-1-yl}propyl)-5-nitrobenzamide
Star0
Identification
- Generic Name
- 3-(alpha-D-galactopyranosyloxy)-N-(3-{4-[3-({2-[(3-{4-[3-({[3-(hexopyranosyloxy)-5-nitrophenyl]carbonyl}amino)propyl]piperazin-1-yl}propyl)amino]-3,4-dioxocyclobut-1-en-1-yl}amino)propyl]piperazin-1-yl}propyl)-5-nitrobenzamide
- DrugBank Accession Number
- DB04210
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 1133.1617
Monoisotopic: 1132.492434794 - Chemical Formula
- C50H72N10O20
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UCholera enterotoxin subunit B Not Available Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Phenolic glycosides
- Alternative Parents
- O-glycosyl compounds / Nitrobenzenes / Phenoxy compounds / Phenol ethers / Nitroaromatic compounds / Secondary alkylarylamines / N-alkylpiperazines / Oxanes / Monosaccharides / Vinylogous amides show 15 more
- Substituents
- 1,4-diazinane / Acetal / Alcohol / Allyl-type 1,3-dipolar organic compound / Amine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / C-nitro compound / Carboximidic acid show 33 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- WWGXKLSKKKQRMN-MLHPNDMTSA-N
- InChI
- InChI=1S/C50H72N10O20/c61-27-35-39(63)43(67)45(69)49(79-35)77-33-23-29(21-31(25-33)59(73)74)47(71)53-7-3-11-57-17-13-55(14-18-57)9-1-5-51-37-38(42(66)41(37)65)52-6-2-10-56-15-19-58(20-16-56)12-4-8-54-48(72)30-22-32(60(75)76)26-34(24-30)78-50-46(70)44(68)40(64)36(28-62)80-50/h21-26,35-36,39-40,43-46,49-52,61-64,67-70H,1-20,27-28H2,(H,53,71)(H,54,72)/t35-,36?,39+,40?,43+,44?,45-,46?,49+,50?/m1/s1
- IUPAC Name
- 3-nitro-N-[3-(4-{3-[(2-{[3-(4-{3-[(3-nitro-5-{[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)formamido]propyl}piperazin-1-yl)propyl]amino}-3,4-dioxocyclobut-1-en-1-yl)amino]propyl}piperazin-1-yl)propyl]-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzamide
- SMILES
- OCC1OC(OC2=CC(=CC(=C2)[N+]([O-])=O)C(=O)NCCCN2CCN(CCCNC3=C(NCCCN4CCN(CCCNC(=O)C5=CC(=CC(O[C@H]6O[C@H](CO)[C@H](O)[C@H](O)[C@H]6O)=C5)[N+]([O-])=O)CC4)C(=O)C3=O)CC2)C(O)C(O)C1O
References
- General References
- Not Available
- External Links
- PDB Entries
- 1rcv
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.775 mg/mL ALOGPS logP 0.2 ALOGPS logP -4.2 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 11.97 Chemaxon pKa (Strongest Basic) 8.26 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 26 Chemaxon Hydrogen Donor Count 12 Chemaxon Polar Surface Area 414.4 Å2 Chemaxon Rotatable Bond Count 28 Chemaxon Refractivity 282.28 m3·mol-1 Chemaxon Polarizability 119.68 Å3 Chemaxon Number of Rings 7 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.6383 Blood Brain Barrier - 0.8897 Caco-2 permeable - 0.65 P-glycoprotein substrate Substrate 0.8771 P-glycoprotein inhibitor I Inhibitor 0.5477 P-glycoprotein inhibitor II Non-inhibitor 0.9242 Renal organic cation transporter Non-inhibitor 0.9 CYP450 2C9 substrate Non-substrate 0.8754 CYP450 2D6 substrate Non-substrate 0.8447 CYP450 3A4 substrate Substrate 0.5787 CYP450 1A2 substrate Non-inhibitor 0.7827 CYP450 2C9 inhibitor Non-inhibitor 0.7869 CYP450 2D6 inhibitor Non-inhibitor 0.8196 CYP450 2C19 inhibitor Non-inhibitor 0.728 CYP450 3A4 inhibitor Non-inhibitor 0.7312 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8281 Ames test AMES toxic 0.5979 Carcinogenicity Non-carcinogens 0.8004 Biodegradation Not ready biodegradable 0.7223 Rat acute toxicity 2.7242 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6445 hERG inhibition (predictor II) Inhibitor 0.7522
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 289.86337 predictedDeepCCS 1.0 (2019) [M+H]+ 291.51657 predictedDeepCCS 1.0 (2019) [M+Na]+ 297.67343 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsCholera enterotoxin subunit B
- Kind
- Protein
- Organism
- Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)
- Pharmacological action
- Unknown
- General Function
- Host cell surface binding
- Specific Function
- The B subunit pentameric ring directs the A subunit to its target by binding to the GM1 gangliosides present on the surface of the intestinal epithelial cells. It can bind five GM1 gangliosides. It...
- Gene Name
- ctxB
- Uniprot ID
- P01556
- Uniprot Name
- Cholera enterotoxin subunit B
- Molecular Weight
- 13957.055 Da
References
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52